Cancer category
|
GMD
|
Agent
|
ρ
|
pFDR
|
Sample size
|
---|
Pancancer
|
KDM2B
|
XMD13-2
|
− 0.4319
|
3.99 × 10–24
|
590
|
Pancancer
|
KDM2B
|
BMS-345541
|
− 0.4313
|
3.99 × 10–24
|
590
|
Pancancer
|
KDM2B
|
T0901317
|
− 0.4231
|
3.83 × 10–23
|
586
|
Pancancer
|
DNMT1
|
Zibotentan
|
− 0.4214
|
3.83 × 10–23
|
591
|
Pancancer
|
KDM2B
|
NPK76-II-72–1
|
− 0.4174
|
1.01 × 10–22
|
591
|
Pancancer
|
APOBEC3G
|
Z-LLNle-CHO
|
− 0.4148
|
2.64 × 10–9
|
225
|
Pancancer
|
KDM2B
|
Zibotentan
|
− 0.4139
|
2.37 × 10–22
|
591
|
Pancancer
|
KDM2B
|
Quizartinib
|
− 0.4095
|
8.98 × 10–22
|
589
|
Pancancer
|
KDM2B
|
UNC1215
|
− 0.4062
|
5.08 × 10–21
|
574
|
Pancancer
|
KDM2B
|
Daporinad
|
− 0.4057
|
7.77 × 10–21
|
569
|
Pancancer
|
KDM2B
|
Vorinostat
|
− 0.4057
|
2.13 × 10–19
|
527
|
Pancancer
|
DNMT1
|
XMD13-2
|
− 0.4043
|
2.87 × 10–21
|
590
|
Pancancer
|
EHMT2
|
NPK76-II-72–1
|
− 0.4041
|
2.87 × 10–21
|
591
|
Pancancer
|
DNMT1
|
Daporinad
|
− 0.4036
|
1.21 × 10–20
|
569
|
Pancancer
|
KDM2B
|
XMD14-99
|
− 0.4035
|
3.24 × 10–21
|
590
|
Pancancer
|
KDM2B
|
BX-912
|
− 0.4031
|
3.37 × 10–21
|
590
|
Pancancer
|
KDM2B
|
I-BET-762
|
− 0.4020
|
5.08 × 10–21
|
587
|
Pancancer
|
KDM2B
|
Tubastatin A
|
− 0.4011
|
5.97 × 10–21
|
587
|
BREAST
|
GADD45A
|
Refametinib
|
− 0.8026
|
0.0002
|
40
|
MATBCL
|
BMI1
|
5-Fluorouracil
|
− 0.7900
|
0.0440
|
27
|
SCLC
|
APOBEC3A
|
GSK1070916
|
0.7764
|
0.0399
|
29
|
BREAST
|
APOBEC3C
|
Cetuximab
|
− 0.7278
|
0.0242
|
38
|
BREAST
|
APOBEC3G
|
Cetuximab
|
− 0.7105
|
0.0399
|
38
|
BREAST
|
GADD45A
|
Trametinib
|
− 0.7012
|
0.0399
|
39
|
NSCLC
|
IDH1
|
(5Z)-7-Oxozeaenol
|
0.5171
|
0.0242
|
91
|
- All agents listed in table were from the GDSC dataset. Abbreviations for cancer categories are provided in Table S2 and in the list of abbreviations. ρ, Spearman correlation coefficient; pFDR, FDR adjusted p-value; Sample size, the number of available cell lines in each category with available RNA-seq expression data and drug response data